Cost-Effectiveness of Olanzapine in the First-Line Treatment of Schizophrenia in China
Autor: | Yanlei Zhang, Ziyi Lin, Yan Cheng, Jianwei Xuan, Jingping Zhao, Kaida Jiang, Qingwei Li |
---|---|
Rok vydání: | 2018 |
Předmět: |
Olanzapine
Orally disintegrating tablet China Pediatrics medicine.medical_specialty Cost effectiveness Cost-Benefit Analysis Drug Compounding Aripiprazole Medication Adherence 03 medical and health sciences 0302 clinical medicine Recurrence medicine Humans health care economics and organizations business.industry 030503 health policy & services Health Policy Public Health Environmental and Occupational Health medicine.disease First line treatment stomatognathic diseases Schizophrenia 030220 oncology & carcinogenesis Health Resources Quality-Adjusted Life Years 0305 other medical science business Models Econometric Antipsychotic Agents medicine.drug |
Zdroj: | Value in Health. 21:S76-S77 |
ISSN: | 1098-3015 |
Popis: | This study aimed to analyze (1) the cost-effectiveness of olanzapine orally disintegrating tablet (ODT) compared to olanzapine standard oral tablet (SOT) and (2) the cost-effectiveness of olanzapine-SOT compared to aripiprazole-SOT for patients with schizophrenia in China.A microsimulation model was adapted from a healthcare payers' perspective. The model ran over a 1-year time horizon, using quarterly cycles. The costs of adverse events were acquired through a clinical expert panel. The average bidding prices in China of olanzapine-ODT, olanzapine-SOT, aripiprazole-SOT, and other switch alternatives were used. Inpatient and outpatient medical costs were sourced from the Urban Employee Basic Medical Insurance database in Tianjin. Additionally, adherence, efficacy, safety, and utility data were taken from the literature. Uncertainty of parameters were assessed through one-way and probabilistic sensitivity analyses.The total annual costs per patient in aripiprazole-SOT arm, olanzapine-SOT arm, and olanzapine-ODT arm are USD 2,296.05, USD 1,940.05, and USD 2,292.81, respectively. The average number of relapses per patient in 1 year in the aripiprazole-SOT arm, olanzapine-SOT arm, and olanzapine-ODT arm, are 0.734, 0.325, and 0.198, respectively. The quality-adjusted life years (QALYs) gained per patient in 1 year in the aripiprazole-SOT arm, olanzapine-SOT arm, and olanzapine-ODT arm are 0.714, 0.737, and 0.758, respectively. Consequently, (1) the incremental cost-effectiveness ratios (ICERs) of administrating olanzapine-ODT over olanzapine-SOT are USD 2,791.96 per relapse avoided and USD 16,798.39 per QALY gained; and (2) the ICERs of using olanzapine-SOT over aripiprazole-SOT are USD -870.39 per relapse avoided and USD -15,477.93 per QALY gained. All ICERs are under the willingness-to-pay threshold in China of USD 25,772.67. The sensitivity analyses confirmed the robustness of the results.As the first-line treatment for schizophrenia in China, olanzapine-ODT is cost-effective compared to olanzapine-SOT and olanzapine-SOT is cost-effective compared to aripiprazole-SOT. |
Databáze: | OpenAIRE |
Externí odkaz: |